If you’ve been waiting patiently on the sidelines for a pullback in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), it’s here. The drug maker’s shares …
Shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) tumbled nearly 5% in after-hours trading Wednesday, after the drug maker announced negative results with GWP42006 in …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares tumble nearly 9% in Friday’s trading session, following the news that competitor Zogenix, Inc. (NASDAQ:ZGNX) achieved impressive results …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares were falling 2% yesterday after the biotech company handed over its third-fiscal quarter print for the year, …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a proprietary combination of tetrahydrocannabinol …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) hosted an analyst meeting last night at the American Epilepsy Society (AES) meeting that was met with marked …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares are on a 6% ascent today after the biotech firm presented additional Epidiolex data from the first …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) announces results from two completed Epidiolex® (cannabidiol or CBD) Phase 3 trials, one in Lennox-Gastaut syndrome (LGS) and …
Joshua Schimmer at Piper Jaffray is chiming in on two biotech players, Gilead Sciences, Inc. (NASDAQ:GILD) and GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), in …
